β2-glycoprotein I peptide inhibitors
AssigneeKansas State University Research Foundation
InventorsSherry Fleming, John M. Tomich
Life of this patent
Estimating the term…
Abstract
Therapeutic peptides (and peptoids) for preventing or inhibiting tissue damage associated with ischemia and/or reperfusion are provided, along with peptides (and peptoids) for preventing or inhibiting cancerous tissue growth. The peptides are derived from β2-glycoprotein I. Pharmaceutical and veterinary compositions comprising the peptides are also provided. Methods of using the peptides to prevent or inhibit tissue damage associated with ischemia and/or reperfusion and/or to prevent or inhibit tissue damage or the growth of cancerous tissue are also provided.
Claims10
A β2-glycoprotein I-derived peptide, said peptide being selected from the group consisting of IHFYX1KNKEKKX1SYTVEDAQX1RDGTI, where each X1 is S (SEQ ID NO. 1);
- KKX1SYTVEDAQX1RDGTIEX2X3X4X1FKEHS, where each X1 is S, X2 is I or V, X3 is P or G, and X4 is R or K (SEQ ID NO. 2);
- KKSSYTVEDAQS (SEQ ID NO. 3);
- residues 3-12 of SEQ ID NO. 3;
- residues 3-12 of SEQ ID NO. 3 with D-amino acids;
- SQADEVTYSS with D-amino acids (SEQ ID NO. 4);
- TEDAQX1IDGTIEV, where each X1 is S (SEQ ID NO. 5);
- KKX1SYTEDAQX1IDGTIEVPKX1FKEHS, where each X1 is S (SEQ ID NO. 7);
- VSFFX1KNKEKKX1SYTEDAQX1IDGTI, where each X1 is S (SEQ ID NO. 8);
- IHFYX1KNKEKKX1SYTVEAHX1RDGTI, where each X1 is S (SEQ ID NO. 9);
- KKSSYTVEAHS (SEQ ID NO. 12);
- residues 3-11 of SEQ ID NO. 12;
- residues 3-11 of SEQ ID NO. 12 with D-amino acids;
- SHAEVTYSS (SEQ ID NO. 13), KKSSYTVEAHSRDGTI (SEQ ID NO. 19), and conservatively modified sequence variants thereof which retain the function of said peptide.
A pharmaceutical or veterinary composition comprising a β2-glycoprotein I-derived peptide, said peptide being dissolved or dispersed in a pharmaceutically-acceptable carrier, wherein said peptide is selected from the group consisting of IHFYX1KNKEKKX1SYTVEDAQX1RDGTI, where each X1 is S (SEQ ID NO. 1);
- KKX1SYTVEDAQX1RDGTIEX2X3X4X1FKEHS, where each X1 is S, X2 is I or V, X3 is P or G, and X4 is R or K (SEQ ID NO. 2);
- KKSSYTVEDAQS (SEQ ID NO. 3);
- residues 3-12 of SEQ ID NO. 3;
- residues 3-12 of SEQ ID NO. 3 with D-amino acids;
- SQADEVTYSS with D-amino acids (SEQ ID NO. 4);
- TEDAQX1IDGTIEV, where each X1 is S (SEQ ID NO. 5);
- KKX1SYTEDAQX1IDGTIEVPKX1FKEHS, where each X1 is S (SEQ ID NO. 7);
- VSFFX1KNKEKKX1SYTEDAQX1IDGTI, where each X1 is S (SEQ ID NO. 8);
- IHFYX1KNKEKKX1SYTVEAHX1RDGTI, where each X1 is S (SEQ ID NO. 9);
- KKSSYTVEAHS (SEQ ID NO. 12);
- residues 3-11 of SEQ ID NO. 12;
- residues 3-11 of SEQ ID NO. 12 with D-amino acids;
- SHAEVTYSS (SEQ ID NO. 13), KKSSYTVEAHSRDGTI (SEQ ID NO. 19), and conservatively modified sequence variants thereof which retain the function of said peptide.
A β2-glycoprotein I-derived peptide and a label, tag, or targeting moiety attached to the C- or N-terminus of said peptide, said peptide being selected from the group consisting of IHFYX1KNKEKKX1SYTVEDAQX1RDGTI, where each X1 is S (SEQ ID NO. 1);
- KKX1SYTVEDAQX1RDGTIEX2X3X4X1FKEHS, where each X1 is S, X2 is I or V, X3 is P or G, and X4 is R or K (SEQ ID NO. 2);
- KKSSYTVEDAQS (SEQ ID NO. 3);
- residues 3-12 of SEQ ID NO. 3;
- residues 3-12 of SEQ ID NO. 3 with D-amino acids;
- SQADEVTYSS with D-amino acids (SEQ ID NO. 4);
- TEDAQX1IDGTIEV, where each X1 is S (SEQ ID NO. 5);
- KKX1SYTEDAQX1IDGTIEVPKX1FKEHS, where each X1 is S (SEQ ID NO. 7);
- VSFFX1KNKEKKX1SYTEDAQX1IDGTI, where each X1 is S (SEQ ID NO. 8);
- IHFYX1KNKEKKX1SYTVEAHX1RDGTI, where each X1 is S (SEQ ID NO. 9);
- KKSSYTVEAHS (SEQ ID NO. 12);
- residues 3-11 of SEQ ID NO. 12;
- residues 3-11 of SEQ ID NO. 12 with D-amino acids;
- SHAEVTYSS (SEQ ID NO. 13), KKSSYTVEAHSRDGTI (SEQ ID NO. 19), and conservatively modified sequence variants thereof which retain the function of said peptide.
Dependencies are inferred from the claim text.